Objective: To review the effects of pharmaceutical care on hospitalizations, mortality and clinical outcomes in patients. Methods: Systematic searches were conducted in MEDLINE, EMBASE and International Pharmaceutical Abstracts (IPA) databases to identify studies that were published between 2004 and January 2017. Studies included in this review were randomized controlled trials (RCTs) that spanned across both community and hospital settings. Using strict inclusion/exclusion criteria studies were included if they reported level 1 or 2 outcomes in the hierarchy of outcome measure i.e. clinical and surrogate outcomes (e.g. blood pressure (BP) control, blood glucose level, cholesterol BMI). Each study was assessed for quality using the Jadad scoring system. Results: Fifty-four RCTs were included in the present review. Forty-six of these studies ranked high quality according to the Jadad scoring system. Studies were categorized into their general condition groups. Interventions in patients with diabetes, depression, respiratory disorders, cardiovascular disorders, epilepsy, osteoporosis, and interventions in older adults were identified. In the majority of studies pharmaceutical care was found to lead to significant improvements in clinical outcomes and/or hospitalizations when compared to the non-intervention group. Some conditions had a large number of RCTs, for example for cardiovascular conditions and in diabetes. Statistically significant improvements were seen in the majority of the studies included for both of these conditions, with studies indicating positive clinical outcomes and/or hospitalizations rates. Within the cardiovascular condition, a subset of studies, focusing on cardiac heart failure and coronary heart disease, had more mixed results. In other conditions the number of RCTs conducted was small and the evidence did not show improvements after pharmaceutical care, i.e. in depression, osteoporosis, and epilepsy. The majority of interventions were face to face interactions with patients, whilst a smaller number were conducted via the telephone and one via a webbased system. Patient education was a key component of most interventions, either verbal and/or written. Longitudinal data, post intervention cessation, was not collected in the majority of cases. Conclusions: RCTs conducted to evaluate pharmaceutical care appear to be effective in improving patient short-term outcomes for a number of conditions including diabetes and cardiovascular conditions, however, other conditions such as depression are less well researched. Future research should attempt to evaluate the conditions where there is a lack of data, whether the positive effects of pharmaceutical care persist in patient populations after the interventions cease and what the long-term clinical outcomes would be of continued pharmaceutical care.
Introduction
Worldwide, the demands on primary health care services are growing, mainly due to an ageing population. 1, 2 The consequence of this is an increased strain on the primary health care workforce 3e6 and as a result, primary health care systems have evolved to encompass new services. In some countries, this has led to extended roles for community pharmacists. 7, 8 The pharmacy profession is evolving worldwide, moving from the traditional role of the technical dispenser to be more patient-focused. 9 The concept of pharmaceutical care was first conceived by Hepler and Strand and is defined as the responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a patient's quality of life. 10 According to the concept of pharmaceutical care, the patient care process is comprised of the establishment of a therapeutic relationship, assessment of medication related problems, development of a care plan, evaluation and continuous follow-up. 11 Pharmacists are responsible for the quality and effectiveness of pharmaceutical care for the benefit of patients to improve their health care outcomes. 12 Since its conception, various terms have been used to describe pharmaceutical care including medication review, medication management, clinical pharmacy services and cognitive services and all of these are defined by similar practices. 13 According to some authors, pharmaceutical care is closely related to medicines management but includes the patient's perspective and pharmacists societal perspective. 14 Pharmacists counsel patients with a focus on educating health management or drug related-problems (identification, resolution or prevention), they develop a care-plan for the individual patient and follow-up the pharmacotherapy. 15 Studies investigating the effects of pharmaceutical care on short and long term patient outcomes have been increasing over the past two decades; however there are mixed reports of whether the pharmaceutical care interventions are effective or not, with the intervention not always showing significant differences.
16e18 Systematic reviews often focus on specific conditions for example, reviews have been conducted in patients with hypertension 19, 20 and in chronic kidney disease 21 and others have looked at pharmaceutical care in specific settings for example, in community pharmacy. 22 A previous systematic review of studies published between 1990 and 2003 was published in 2005. This review evaluated the effectiveness of pharmaceutical care across all conditions and concluded that the pharmaceutical care is effective in improving surrogate outcomes but less conclusive in other outcomes. 23 Evidence of the effect of pharmaceutical care is constantly growing and regular systematic evaluation is important and relevant to healthcare. This current study included randomized controlled trials (RCTs) published since 2004 across all conditions, to evaluate the evidence of whether pharmaceutical care is effective for patients. The objective of this systematic review was to examine the effects of pharmaceutical care using patient outcomes (i.e. clinical and surrogate outcomes) in both the hospital and community setting.
Methods

Search strategy
The PRISMA guidelines for conducting the systematic review were followed. A systematic search of the literature was conducted to identify RCTs published in English language between 2004 and January 2017 by using the electronic databases: Medline (Ovid SP), International Pharmaceutical Abstracts (IPA) and Embase. Our search included both mapped and unmapped terms, which are illustrated in Fig. 1 . In addition, the following text words and MeSH/ EMTREE terms were used to see if there were any additional relevant papers: The databases were searched for the following key terms in combination where appropriate: ("Pharmaceutical services"), ("Pharmaceutical care"), ("Medicine management"), ("Medicine therapy assessment"), ("Medicine therapy management"), ("Drug therapy management") ("Pharmacy services") ("Medication review"), ("Comprehensive medication review"), ("drug utilization management"), ("Drug therapy services"), ("Pharmacist intervention") and ("Patient centered care" and Medicines" or "Drug" or "Pharmac*"). We combined these keywords with the filter "Randomized controlled trial", if the filter was not available on that data base then a keyword was used and the study's methodology was evaluated to ensure only randomized controlled trials were included. See Fig. 1 for Prisma flow diagram.
Inclusion/exclusion criteria
The inclusion and exclusion criteria are detailed in Table 1 . Studies were included in this review if they referred to a pharmaceutical care intervention in adult patients and the intervention included the role/input of a pharmacist. All healthcare settings No outcomes relevant to decreasing medical errors and/or adverse events (e.g., study with patient satisfaction as only measured outcome; article describes an approach to detecting errors but reports no measured outcomes)
were included i.e. both hospital and community based interventions. Studies were excluded if they were not written in English, did not have a full text article available, or if they were reviews, commentaries or letters to the editor. Studies published before 2004 were also excluded. Our review's aim was to evaluate RCTs that assessed pharmaceutical care, so all studies were excluded if they were not RCTs, including cluster RCTs and any pilot data. RCTs were only included in this review if they measured patient outcomes that were either level 1 or 2 in the hierarchy of outcome measures (Table 2 .)
Jadad scores of methodology quality
A quality assessment was completed for each randomized controlled trial using the Jadad checklist. 24 A Jadad score of equal to or greater than 3 is indicative of a high-quality study. 19 The assessment criteria for the Jadad scoring are detailed in Fig. 2 . The Jadad score has been used as a tool in previous literature evaluating RCTs. 19, 25 3. Results
Studies selection
The literature search identified 669 titles/abstracts that contained the aforementioned key terms. The titles and abstracts of all selected articles were reviewed for relevance. The search results were further checked and reviewed by a second author. In case of any doubt regarding papers, the full text article was reviewed for relevance. Inclusion criteria were formulated in relation to the research aims.
A total of 218 studies were screened and assessed for eligibility. Of these 54 RCTs fulfilled the inclusion criteria. The flow diagram (Fig. 1) details the process in which the studies were identified, screened and included in this review. The inclusion and exclusion criteria of study are summarized in Table 1 .
Data extraction and analysis
Two researchers (LC, RK) independently extracted study characteristics, using an extraction table. One researcher (LC) compared all extracted data and discussed discrepancies with other researchers (ZB) when necessary. The data were then grouped based on the condition that they aligned with and a summary of the data extracted from the studies is presented in Tables 3e8. This includes the country of origin, patient group included, follow-up period, number of patients in each arm, setting, description of the intervention outcomes measured, level of hierarchy of outcome measured and a summary of results.
Studies characteristics
The included studies (n ¼ 54) were performed over a number of
States of America (USA) (n ¼ 8) and United Arab Emirates (UAE) (n ¼ 3). All of the studies were conducted within the specified country, i.e. not over more than one country.
The targeted population included patients with specific condition(s) or those on a specific therapy. The RCTs can be further categorized into the following categories based on therapeutic condition; cardiovascular (CV) conditions (n ¼ 24), diabetes (n ¼ 15), depression (n ¼ 2), older adults (n ¼ 6), respiratory (n ¼ 3) conditions or other studies (those on multiple medicines, osteoporosis and epilepsy). 4 The RCTs included in the review involved follow up period from 30 days to 36 months. The most common follow-up periods were as follows: 19 RCTs included interventions with a follow up period of 6 months, seventeen RCTs with 12 months, and six studies with 3 months follow-up. Follow-up was conducted in some studies by face-to-face meetings; others used web-based communications and telephone contact.
Jadad scores of methodology quality
Randomized controlled trials with a Jadad score equal to or greater than 3 are indicative of a high-quality study. 19 In this review the Jadad scores were recorded in the data extraction tables. Fortysix of the studies in this review ranked 3 or above in the Jadad scale. One study ranked a 5 score. The main reason for loss of points on this score chart was nature of the study design i.e. not being double-blinded.
Interventions
The majority of the pharmaceutical care interventions assessed by RCTs in this review included educational interventions for patients. Educational interventions involved the verbal or written information to improve the knowledge and awareness of patients regarding their diseases. Behavioral interventions included changes in patient compliance by modifying their attitude to medication adherence to drug therapy.
Some RCTs used one of the above interventions as single and others applied in combination (multifaceted). The interventions were applied and their effects on patient's health care outcomes including clinical outcomes (morbidity, mortality, and hospitalizations) and surrogate clinical outcomes (laboratory results) were measured. Tables 3e8 summarizes important characteristics of the studies included in the review. Some studies used the Dader method of pharmaceutical care. This method includes "patient education about CV drugs, completion of a drug therapy profile and/or drug history, assessment of drug compliance, patient counselling about lifestyle modifications, pharmacist-performed interventions not related to changes in drug therapy, and pharmacist-delivered treatment recommendations to physicians". 27 In many RCTs in this review, follow-up took place on a frequent regular basis through the study, whereby a pharmacist contacted the patient either via home visits, appointments or via the telephone.
Outcomes
This review sought to identify RCTs that had evaluated pharmaceutical care interventions in patients across all conditions. The outcomes that we were interested in were those that are described in Table 2 , meeting criteria one or two, i.e. hospitalizations or unintended use of medical care, mortality and clinical outcomes that have been shown to be directly related to the progression/severity of the condition. In some instances these studies also reported other measures, which have been included in the table for completeness but are not discussed in the results section. Criteria that each study reported are recorded in the level of outcome measure in Tables 3e8.
Impact of pharmaceutical care in disease management
3.7.1. Cardiovascular disorders (Table 3) Twenty-four RCTs evaluated the impact of pharmaceutical care on the patients with cardiovascular diseases, of which 20 showed statistically significant clinical outcomes. 27 45 The four studies that did not show significant differences in hospitalizations or clinical outcomes were in cardiac heart failure patients 36 and three in those with coronary heart disease. 29, 33, 37 To note, two studies included patients that had been diagnosed with diabetes and cardiovascular conditions; these studies were included and discussed in the diabetes section.
Clinical outcomes measured included BP, cholesterol levels blood glucose and cardiovascular risk. Eleven studies found significant differences in diastolic and/or systolic BP readings after the intervention. 27, 30, 34, 35, 38, 39, 41, 46, 48, 50, 51 One study specifically aimed to evaluate whether patients met a target BP. 46 Two studies found no significant differences in BP; one study by Garcia and colleagues 33 and another by Sadiq et al. 47 Cholesterol readings were compared in twelve RCTs 27,29,31,33,35,38e40,43e45,49 ; these measures included total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-c), and/or high density lipoprotein cholesterol (HDL-c) levels. Statistically significant differences were seen in TC, 27 39 Blood glucose was measured in two of the studies, but neither reported significant differences. 33, 35 Cardiovascular risk was calculated and compared in two studies. One study showed a significant reduction in CV risk after the intervention, 31 but the other study showed no differences. 29 Hospitalization rates were recorded Murray and colleagues, who found statistically significant differences after a pharmacist intervention in patients with low incomes and heart failure, however this difference dissipated after the intervention stopped 42 Furthermore, Holland et al. reported no significant differences in patients with cardiac heart failure after pharmacist intervention post-discharge from hospital. Unplanned health care utilization was found to be statistically significant in patients with low health literacy in the study by Bell et al. 28 Another study in patients with cardiac heart failure used exercise tolerance (2-min walk), and forced vital capacity in order to evaluate the intervention, in addition to the measures described above. Statistical significant differences were found in both measures. 47 Lalonde and colleagues' RCT included patients who had been prescribed warfarin. They evaluated whether there were changes in INR control, complications and use of health care services, and found no differences after intervention by a pharmacist anticoagulation service. 37 
Diabetes mellitus (Table 4)
Fifteen of the RCTs assessed the effect of pharmaceutical care intervention on various outcomes of the patients diagnosed with diabetes mellitus ( Hospitalizations and unexpected medical usage was recorded by a number of studies, but only reached statistical significance after a pharmaceutical care intervention in one study. 66 
Respiratory conditions (Table 5)
Three studies evaluated the impact of pharmaceutical care and medicines management on the respiratory disorders patients including asthma and chronic obstructive pulmonary diseases (COPD) ( Table 5 ). Two of these solely involved the COPD 76, 77 and one patients with asthma. 75 Statistical significant differences were found in symptoms of the conditions i.e. frequency of attacks, nocturnal symptoms and frequency of reliever use in asthmatics 75 and exacerbations in COPD. 77 In addition hospitalization rates were also statistically significant after intervention with pharmaceutical care. 76, 77 3.7.4. Depression (Table 6 ) Two RCTs included in this review focused on pharmaceutical care interventions in depression. Clinical outcomes measuring clinical severity in the intervention groups led to mixed results. One study found a significant difference 67 in clinical measures whereas the other did not. 68 The latter study did lead to significant changes in HRQOL but not clinical severity. Pharmaceutical care was performed The appropriateness of treatment was analyzed, and a pharmaceutical care plan was prepared. At discharge, the pharmacist provided written and oral information on treatment changes to the patient or caregiver, as well as written information to the general practitioner.
Medication Appropriateness Index (MAI), Beers criteria, and Assessing Care of Vulnerable Elders (ACOVE) underuse criteria and mortality, readmission, and emergency visits. 3.7.5. Older adults (Table 7) Six studies evaluated pharmaceutical care interventions in older adults, with mixed results (Table 6) ; four studies showed statistical significance in clinical outcomes or hospitalizations, 69e71,74 whereas two showed no difference. 72, 73 Hospitalization rates were reported in all of the six RCTs, with two studies finding differences after intervention of pharmaceutical care. 69, 70 One study reported significant differences in worsening of pain 69 and three studies reported improvements in appropriateness 74 or number 71,72 of medicine prescribed. (Table 8) 3.8.1. Multiple medications Two RCTs involved the implementation of interventions for patients who were on multiple medications; one study patients included in the RCT needed to be taking a minimum of three medicines 78 and the second study the patients needed to be taking five or more medications. 81 The study by Basheti and colleagues 78 was community pharmacy based using a medication management review and the primary outcome was resolution of drug related problems, acceptance of advice by prescribers plus clinical outcomes of blood glucose levels, BP and triglyceride levels. Significant differences were seen in drug related problems resolved and all clinical outcomes. 78 The second study in this category was set in a specialist medical center and the primary endpoint was death of any cause and rate of hospitalizations. Differences were found in number of deaths. (Table 8 ).
Other studies included
The primary outcome was health related quality of life (HRQOL) measured by Quality of Life in Epilepsy Inventory-31 (QOLIE-31) and the secondary outcomes included the changes in frequency of seizures, depression measured by using the questionnaire of the Center for Epidemiologic Studies Depression Scale (CES-D), adverse drug reactions by Liverpool Adverse Event Profile (Liverpool AEP) and adherence by using Haynes-Sackett test and Moriski-Green test. Significant differences were seen in QOLIE-31 scores. No significant differences were seen in the frequency of seizures.
Osteoporosis
A RCT assessed the effects of pharmaceutical care on adherence and persistence of bisphosphonate in postmenopausal osteoporotic women. 79 Primary outcome measures were medication adherence, bone turnover markers (BTMs) and persistence (Table 8) . Two BTMs serum C-terminal cross-linking telopeptide of type I collagen (CTX-I) and serum osteocalcin (OC) were assessed. No significant reduction was found in CTX-1 and OC between the two groups. 
Discussion
This systematic review aimed to evaluate the effectiveness of pharmaceutical care, based on RCTs that have been published between 2004 and January 2017. There have been a steady number of studies emerging over the past decade evaluating pharmaceutical care, leading to a high number of studies that were included in this review. Our findings suggest that pharmaceutical care, in the majority of cases, is effective in either decreasing hospitalizations or improving surrogate clinical outcomes particular to the presenting condition. The included studies are all RCTs, which are considered the gold standard of clinical effectiveness if the methodology is properly executed, 19 however RCTs in pharmaceutical care are often challenging to conduct and this could be a reason for a bias toward In addition to the current literature, our review has identified that there is strong evidence to support pharmaceutical care in long term conditions affecting patients with hypertension and dyslipidemia. Surrogate clinical outcomes of BP and cholesterol levels have shown to be systematically improved in the majority of studies; interestingly despite these two biomarkers being integral to the calculation of 5-year cardiovascular risk, only one study (out of two) showed significant improvements in 5-year cardiovascular risk. A systematic review published by Aguiar and colleagues 9 focused on pharmaceutical care in hypertensive patients and found similar results to the present study. 19 Systolic BP was the most positively impacted clinical outcome by the pharmaceutical intervention. The authors of the 2012 review described the need to improve research design, as there were limitations in hardiness. 19 In 2011 Morgado and colleagues conducted a systematic review and meta-analysis of pharmacist interventions to enhance BP therapy; results of this review showed that pharmacist interventions can significantly improve medication adherence, systolic BP, diastolic BP, and BP control in patients with essential hypertension. 20 However in this review, one important limitation noted by the authors were the databases available for the systematic review, potentially therefore missing potential eligible studies. In this review, the outcomes in relation to CHF and CHD were mixed. In is not as clear whether pharmacist intervention via pharmaceutical care is as effective; this may be due to fewer RCTs available in these conditions. In 2008 Koshman et al. published a systematic review in patients with CHF, including studies prior to 2007. Despite inclusion of 12 RCTs, outcomes were similar to our current review; mixed results for HF hospitalizations (3 of 11 studies finding significant differences) and mortality rates showing no significant differences. Overall, when the authors of this study pooled responses for outcomes, benefits were seen in pharmacist intervention. 85 Further studies need to be conducted to clarify the effectiveness of pharmacists in these conditions. Pharmacists play a significant role in the provision of a pharmaceutical care services in diabetes mellitus. Our findings show strong evidence that pharmaceutical care interventions have significant positive effects in the reduction of HbA1c level in patients with diabetes. This finding is similar to other studies that have focused on diabetes, for example Fornos et al. 86 and Balaiah et al., 87 where glycemic control was found to be significantly improved as a result of pharmaceutical care interventions; ultimately lowering of HbA1c being a predictor of improved therapeutic outcomes of patients.
88
A previous Cochrane review did not show that pharmaceutical care is effective in older adults, 89 this current review reported mixed outcomes for hospitalizations and included measures of appropriateness of medications and health related quality of life. Our study focused on surrogate clinical outcomes and hospitalizations and included six RCTs, with an overall unclear conclusion regarding the benefit of pharmaceutical care intervention in this population. Four studies showed improvements after pharmaceutical care interventions, whilst two did not. This is also in line with a previous review by Holland and colleagues who concluded that pharmaceutical care does not impact on hospitalizations and mortality, however the authors do suggest that interventions could potentially improve knowledge and adherence. 90 The three respiratory studies were included in this review, all showed significant changes after a pharmaceutical care intervention. Health resource utilization, 76,77 symptoms 77 and inhalation techniques 76 were found to be improved in COPD patients. Similar results were seen in asthmatic patients, with improvements in symptoms, frequency of attached and reliever use. 75 No significant differences in hospitalizations or clinical surrogate outcomes were seen in patients with epilepsy, osteoporosis and depression. This could be due to the limited studies that have been conducted, and in the case of the study by Losada-Camacho et al. a relatively low number of patients returned their seizure diary. 80 Like previous literature, this study highlights the potential that pharmaceutical care has in a number of conditions, but goes further to identify some conditions that pharmaceutical care may not lead to changes in clinical outcomes. These non-significant results are challenging to interpret, they could be due to a myriad of factors including shorter follow up period insufficient for the examination of intervention effects and measurement of endpoints, the training of the pharmacists involved, the frequency of monitoring in the staff and the nature of those follow-up sessions.
This review also highlights the need for consistency across studies in the future in terms of the clinical outcomes measured. Despite grouping the studies in this review into condition groups, within each condition there was a wide range of outcomes reported. This makes it challenging to be able to conduct a metaanalysis. Only the cardiovascular and diabetes section had a sufficient number of studies to be able to further assess a subset of the condition, for example blood pressure. However, if a meta-analysis were to be conducted on such a specific subset, it may most appropriate to include all RCTs that have been conducted on the topic, with no date limitation. This is out of the scope of this potential review, but could be the topic of future research. If there could be a consensus of future research to all collect data on a specific outcome, a meta-analysis could be conducted to look at pharmaceutical care overall.
Currently there is a gap in current knowledge regarding the long term effects of pharmaceutical care interventions. Cooper and colleagues reported that patients show improvements in the first six months of interventions due to the psychological effects of being monitored, and this often drops off thereafter. 91 The most frequently used follow up time in our review was six months, and one study did note that the beneficial effects seen dissipated when the intervention ceased. 42 Future intervention studies with pharmaceutical care should bear this in mind. One of the studies in our review did have a sham intervention condition, and this study did find significant differences after pharmaceutical care. 30 Possibly future studies should aim to have a sham arm to the trial, therefore the pharmaceutical care aspect of the intervention can be differentiated in the methodology. 19 In addition long term consequences of these interventions should be examined. The present study has certain limitations. The study is limited to the English language literature and studies in other languages were not included. Only original research RCTs are included in the review; secondary studies were excluded. This study also included the specific outcomes of hospitalizations, mortality and surrogate clinical outcomes, therefore not incorporating HRQOL score, patient satisfaction or adherence scores, future studies could focus on these aspects to evaluate the full spectrum of pharmaceutical care effects on patients.
Conclusion
RCTs conducted to evaluate pharmaceutical care appear to be effective in improving patient short-term outcomes for a number of conditions including diabetes and cardiovascular conditions, however, other conditions such as depression are less well researched. Future research should attempt to evaluate whether these effects persist and the long-term clinical outcomes.
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